Patients with a partial response
. | Group 1 . | Group 2 . | Group 3 . | All patients . | ||||
---|---|---|---|---|---|---|---|---|
Population . | n/n (%) . | 95% CI . | n/n (%) . | 95% CI . | n/n (%) . | 95% CI . | n/n (%) . | 95% CI . |
All patients | 4/13 (31) | 9.1, 61.4 | 1/11 (9) | 0.2, 41.3 | 3/9 (33) | 7.5, 70.1 | 8/33 (24) | 11.1, 42.3 |
Stage less than IIB* | 0/2 (0) | 0.0, 84.2 | 0/1 (0) | 0.0, 97.5 | 1/2 (50) | 1.3, 98.7 | 1/5 (20) | 0.5, 71.6 |
Stage at least IIB† | 4/11 (36) | 10.9, 69.2 | 1/10 (10) | 0.3, 44.5 | 2/7 (29) | 3.7, 71.0 | 7/28 (25) | 10.7, 44.9 |
Sezary syndrome | 1/3 (33) | 0.8, 90.6 | 1/4 (25) | 0.6, 80.6 | 2/4 (50) | 6.8, 93.2 | 4/11 (36) | 10.9, 69.2 |
. | Group 1 . | Group 2 . | Group 3 . | All patients . | ||||
---|---|---|---|---|---|---|---|---|
Population . | n/n (%) . | 95% CI . | n/n (%) . | 95% CI . | n/n (%) . | 95% CI . | n/n (%) . | 95% CI . |
All patients | 4/13 (31) | 9.1, 61.4 | 1/11 (9) | 0.2, 41.3 | 3/9 (33) | 7.5, 70.1 | 8/33 (24) | 11.1, 42.3 |
Stage less than IIB* | 0/2 (0) | 0.0, 84.2 | 0/1 (0) | 0.0, 97.5 | 1/2 (50) | 1.3, 98.7 | 1/5 (20) | 0.5, 71.6 |
Stage at least IIB† | 4/11 (36) | 10.9, 69.2 | 1/10 (10) | 0.3, 44.5 | 2/7 (29) | 3.7, 71.0 | 7/28 (25) | 10.7, 44.9 |
Sezary syndrome | 1/3 (33) | 0.8, 90.6 | 1/4 (25) | 0.6, 80.6 | 2/4 (50) | 6.8, 93.2 | 4/11 (36) | 10.9, 69.2 |